Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Fondaparinux in an obese child with heparin-induced thrombocytopenia and a history of renal failure.
[heparin-induced thrombocytopenia]
A
9
-
year
-old
obese
child
with
a
history
of
ulcerative
colitis
was
admitted
to
the
intensive
care
unit
for
significant
blood
loss
,
hemorrhagic
shock
,
and
acute
renal
failure
.
Following
complications
from
total
colectomy
secondary
to
multiple
perforations
,
the
patient
developed
heparin-induced
thrombocytopenia
(
HIT
)
and
subsequent
portal
vein
thrombosis
.
Subcutaneous
(
SQ
)
fondaparinux
therapy
was
initiated
because
the
patient
was
unable
to
transition
to
oral
anticoagulation
.
An
anti-
factor
Xa
assay
was
developed
and
used
to
adjust
his
fondaparinux
therapy
.
Based
on
hemorrhagic
complications
and
fondaparinux-based
anti-
factor
Xa
assay
results
,
the
fondaparinux
was
adjusted
to
a
final
dosage
of
4
.
5
mg
(
0
.
066
mg
/
kg
)
SQ
daily
.
In
children
unable
to
transition
to
oral
anticoagulation
,
fondaparinux
may
be
an
alternative
for
the
treatment
of
thrombosis
associated
with
HIT
.
We
noted
that
our
patient
required
a
lower
dose
per
kilogram
of
fondaparinux
than
described
in
previous
published
reports
.
Despite
this
lower
dosage
per
kilogram
,
our
patient
developed
bleeding
despite
dosage
reductions
;
subsequently
,
a
few
doses
were
held
.
It
is
unclear
if
this
was
related
to
his
obesity
,
history
of
renal
failure
,
or
a
combination
of
factors
.
Future
studies
should
determine
the
optimal
dose
for
special
populations
of
children
(
e
.
g
.
,
those
with
obesity
and
renal
failure
)
.
Until
then
,
clinicians
should
routinely
monitor
and
titrate
fondaparinux
therapy
,
ideally
using
a
fondaparinux-
specific
anti-
factor
Xa
assay
.
Diseases
Validation
Diseases presenting
"hemorrhagic shock"
symptom
heparin-induced thrombocytopenia
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom